Navigation Links
Encorium Group Updates Expected Timeframe with Respect to the Sale of its U.S. Business
Date:7/1/2009

s; (xi) announced awards received from existing and potential customers are not definitive until fully negotiated contracts are executed by the parties; (xii) our backlog may not be indicative of future results and may not generate the revenues expected; (xiii) our ability to successfully integrate the business of Remedium OY, which we acquired on November 1, 2006; (xiv) the performance of the combined businesses to operate successfully and generate growth; and (xv) uncertainties regarding the availability of additional capital and continued listing of our common stock on Nasdaq. You should not place undue reliance on any forward-looking statement. We undertake no obligation to publicly release the result of any revision of these forward-looking statements to reflect events or circumstances after the date they are made or to reflect the occurrence of unanticipated events. Please refer to the section entitled "Risk Factors" in the Form 10-K for a more complete discussion of factors which could cause our actual results and financial position to change.

You should not place any undue reliance on these forward-looking statements which speak only as of the date of this press release. Additional information concerning factors that might affect our business or stock price which could cause actual results to materially differ from those in forward-looking statements is contained in Encorium Group's SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2008 and other periodic reports under the Securities Exchange Act of 1934, as amended, copies of which are available upon request from Encorium Group's investor relations department.

www.encorium.com


'/>"/>
SOURCE Encorium Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Encorium Appoints David Ginsberg President and Chief Executive Officer, Announces Changes to the Board of Directors
2. Encorium Reports Third Quarter 2008 Financial Results
3. Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing
4. Encorium Group Signs $3.1 Million of New Business Contracts Including an Extension of a Current U.S. Oncology Clinical Trial with a Major Pharmaceutical Company
5. Encorium Group Signs Approximately $2.0 Million of New Business Contracts
6. Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award
7. Professor Hanna Nohynek Joins Encorium as Head Consultant of its Clinical Vaccine Research Team
8. Avicena Group to Present at Noble Financial Conference
9. Chrome Group to Seek Listing for Some of its Subsidiaries
10. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
11. Reed Group to Provide MDA Internet Disability Duration Guidelines to U.S. Navy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... March 04, 2015 Follow us ... one of the fastest growing technologies in the life ... subcellular visualization is driving growth in nucleic acid detection ... understanding of gene expressions will continue to benefit the ... in fields ranging from pharma, biotech, food & beverage ...
(Date:3/4/2015)... 2015 Lancée par ... en décembre 2011, l,étude collaborative française ... qui compare   l es microsphères en ... dans le carcinome hépatocellulaire avancé, a recruté plus ... avancé   ; les résultats sont attendus fin ...
(Date:3/3/2015)... March 3, 2015 /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: ... and molecular diagnostics that target the underlying mechanisms of ... seventh-month period ended December 31, 2014. Effective ... end from May 31 to December 31. As a ... today are for the quarter and the seven months ...
(Date:3/3/2015)... , March 3, 2015 NASA astronaut Scott ... this month to spend a year living and working on ... interviews from 5:30 to 7 a.m. EDT Monday, March 9. ... as he completes the final weeks of his training. ... video on NASA Television highlighting his mission training and previous ...
Breaking Biology Technology:Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 2Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 2Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 5Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12NASA Astronaut Scott Kelly Available for Interviews before One-Year Space Station Mission 2
... StentForms Alliance to Jointly Develop Drug Eluting Balloon ... today that that the company entered into a ... subsidiary of Opto Circuits (OCI) Ltd., by which ... Genius MAGIC Cobalt Chromium Coronary Stent System for ...
... based Mayuka Labs,Private Limited has received recognition for its ... and industrial,research (DSIR) under the ministry of science and ... twenty-one scientists working round the clock at its R&D ... milestone in its first year of,operations. The company has ...
... Inc. (OTC: NNLX) a biotechnology company, announces director appointments ... Jeff Long to the Board of Directors. Daniel Barnhizer ... State University College of Law, where he teaches ... and commercial law. In addition to his academic work, ...
Cached Biology Technology:Micell Forges Strategic Agreement to Develop Advanced Drug-Eluting Stents and Balloons 2Micell Forges Strategic Agreement to Develop Advanced Drug-Eluting Stents and Balloons 3Mayuka Labs R&D Centre Gets DSIR Recognition 2NanoLogix Inc. Appoints Two New Directors and Provides Operations Update 2NanoLogix Inc. Appoints Two New Directors and Provides Operations Update 3
(Date:2/5/2015)... 2015 Despite a lack of advancements ... as consumer electronics, automotive, storage and telecommunication has ... (SMT) screen printers. Innovations in electronics and conversion ... the adoption curve up. Meanwhile, sale volumes of ... dispensers are indispensable in the production of complex ...
(Date:1/22/2015)... ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to inform its shareholders ... Washington,s Department of Licensing, in the United States, awarded ... for driver,s licenses and identification cards to its subsidiary, Valid ... start in January 2015, with enrollment and card production starting ...
(Date:1/22/2015)...  Today, FreeWavz ( www.FreeWavz.com ), the developer of ... Fundable, https://www.fundable.com/freewavz . FreeWavz will be expanding ... meet customer demand. Logo - ... Invented by Dr. Eric ...
Breaking Biology News(10 mins):End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3Valid USA Signs Contract For Washington Driver's License Issuance 2FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2
... have for the first time discovered sixteen new sections of ... opening up the possibility for better prevention as well as ... scientists from 126 centres in Europe, the USA and Australia ... lung. Their discovery sheds new light on the molecular ...
... Genetic parasites invaded the mammalian genome more than 100 ... -- transforming the uterus in the ancestors of humans and ... home for developing young, a new Yale University study has ... journal Nature Genetics describe in unprecedented detail the ...
... non-steroidal anti-inflammatory drugs (NSAIDs) the subjects of ... to reveal about how they work., Vanderbilt University ... actions of NSAIDs. Their findings, reported Sept. 25 ... developing a new class of inflammation- and pain-fighting ...
Cached Biology News:New discoveries in genetics of lung health 2Invasion of genomic parasites triggered modern mammalian pregnancy 2Study puts a new spin on ibuprofen's actions 2
Glucagon-like peptide-1 (GLP-1 (1-36) amide)...
Complement factor B (human)...
... NH2-terminal kinase) signal transduction cascade is ... pathways in mammals. JNK pathway activation ... is associated with the nuclear accumulation ... in the immune response, cellular proliferation, ...
... near- and far-infrared range FT-IR spectrometers give ... their class. Yet all this comes at ... throughput: Having a larger and faster ... other conventional FT-IRs provides 300%,larger solid angle ...
Biology Products: